In an early-stage NSCLC patient with treatment history of adjuvant chemotherapy plus gefitinib, dual mutations of ALK-R3HDM1 (A19: R21) and EML4-ALK (E6: A20, variant 3) rearrangement were detected in his metastatic lymph node. The gene discussed is ALK; the disease is non-small cell lung carcinoma.